The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: Experimental data

BJU International

Volumn 102, Issue 5, 2008, Pages 622-627

  Lo Nigro, Cristiana ^a   Maffi, Monica ^a   Fischel, Jean Louis ^b   Formento, Patricia ^b   Milano, Gerard ^b   Merlano, Marco ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Androgen independent prostate cancer; Docetaxel; Lanreotide; MDR1; PC3 cell line

Indexed keywords

ANDROGEN; ANGIOPEPTIN; DOCETAXEL; GLYCOPROTEIN P; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG FORMULATION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; MONOTHERAPY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG EVALUATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASMS, HORMONE-DEPENDENT; PEPTIDES, CYCLIC; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SOMATOSTATIN; TAXOIDS;

EID: 48749111500     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07706.x     Document Type: Article

References (20)

1. Zelivianski S, Spellman M, Kellerman M et al. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 2003 107 : 478 85
2. Legrier ME, Oudard S, Judde JG et al. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer 2007 96 : 269 76
3. Tannock IF, de Wit R, Berry WR et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351 : 1502 12
4. Seidman R, Gitelman I, Sagi O, Horwitz SB, Wolfson M. The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Exp Cell Res 2001 268 : 84 92
5. Boldt S, Weidle UH, Kolch W. The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 2002 23 : 1831 8
6. Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002 13 : 653 68
7. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006 17 : 1733 42
8. Ferjoux G, Lopez F, Esteve JP et al. Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Mol Biol Cell 2003 14 : 3911 28
9. Sullivan A, Syed N, Gasco M et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004 23 : 3328 37
10. Kubota A, Yamada Y, Kagimoto S et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994 93 : 1321 5
11. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987 47 : 936 42
12. Altenberg GA, Vanoye CG, Horton JK, Reuss L. Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane. Proc Natl Acad Sci USA 1994 91 : 4654 7
13. Beer TM, El-Geneidi M, Eilers KM. Docetaxel (Docetaxel) in the treatment of prostate cancer. Expert Rev Anticancer Ther 2003 3 : 261 8
14. Li Y, Hussain M, Sarkar SH, Eliason J, Li R, Sarkar FH. Gene expression profiling revealed novel mechanism of action of docetaxel and Furtulon in prostate cancer cells. BMC Cancer 2005 5 : 7
15. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999 6 : 503 19
16. Lahlou H, Saint-Laurent N, Esteve JP et al. sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 2003 278 : 39356 71
17. Charland S, Boucher MJ, Houde M, Rivard N. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 2001 142 : 121 8
18. Pages P, Benali N, Saint-Laurent N et al. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27 (Kip1). Evidence for the role of SHP-1. J Biol Chem 1999 274 : 15186 93
19. Theodoropoulou M, Zhang J, Laupheimer S et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 2006 66 : 1576 82
20. Uchiyama-Kokubu N, Naito M, Nakajima M, Tsuruo T. Transport of somatostatin and substance P by human P-glycoprotein. FEBS Lett 2004 574 : 55 61